Get notified when CTOR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, with capital sufficient only through September 2025 after the July 2025 financing.
NASDAQ: CTOR CITIUS ONCOLOGY, INC. 424B5

Citius Oncology prices $9.0M registered direct offering at $1.75/share with warrants

Filed September 10, 2025 · ~1 min read

Key Changes

  • high

    Citius Oncology is selling 5,142,858 shares at $1.75 per share in a registered direct offering to a single investor, raising $9.0M gross before fees.

    The Offering verify on EDGAR →
  • high

    The company estimates net proceeds of approximately $7.48M after placement agent fees and expenses, to fund LYMPHIR commercialization and working capital.

    Use of Proceeds verify on EDGAR →
  • high

    New investors face immediate dilution of $2.06 per share, as net tangible book value per share after the offering is negative $0.312.

    Dilution verify on EDGAR →

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PLAY 10-Q) is open in full — no account needed.

Partner

Trade CTOR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify